![Shulamit Ron-Bigger](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Shulamit Ron-Bigger
Direttore operativo presso Aktis Oncology, Inc.
Posizioni attive di Shulamit Ron-Bigger
Società | Posizione | Inizio | Fine |
---|---|---|---|
Aktis Oncology, Inc.
![]() Aktis Oncology, Inc. Medical/Nursing ServicesHealth Services Aktis Oncology, Inc. is a biotechnology company located in Boston, MA. The company specializes in the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. The company's molecules are designed for high tumor penetration and long residence time, which maximizes tumor elimination while minimizing side effects of treatment. The approach enables clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. Founded and incubated by MPM Capital, Aktis Oncology has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Matt M. Roden has been the CEO of the company since 2020. | Direttore operativo | 19/09/2022 | - |
Storia della carriera di Shulamit Ron-Bigger
Formazione di Shulamit Ron-Bigger
The Hebrew University of Jerusalem | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 2 |
Israele | 2 |
Posizioni
Chief Operating Officer | 1 |
Doctorate Degree | 1 |
Settori
Health Services | 2 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Aziende private | 1 |
---|---|
Aktis Oncology, Inc.
![]() Aktis Oncology, Inc. Medical/Nursing ServicesHealth Services Aktis Oncology, Inc. is a biotechnology company located in Boston, MA. The company specializes in the discovery and development of a new class of targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. The company's molecules are designed for high tumor penetration and long residence time, which maximizes tumor elimination while minimizing side effects of treatment. The approach enables clinicians to visualize and verify target engagement prior to exposure to therapeutic radioisotopes. Founded and incubated by MPM Capital, Aktis Oncology has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy. Matt M. Roden has been the CEO of the company since 2020. | Health Services |
- Borsa valori
- Insiders
- Shulamit Ron-Bigger
- Esperienza